Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MYGN 
Myriad Genetics Inc (MYGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: MYGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $7.38
1 Year Target Price $7.38
| 3 | Strong Buy |
| 3 | Buy |
| 6 | Hold |
| 2 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.31% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 697.83M USD | Price to earnings Ratio - | 1Y Target Price 7.38 |
Price to earnings Ratio - | 1Y Target Price 7.38 | ||
Volume (30-day avg) 15 | Beta 1.94 | 52 Weeks Range 3.76 - 29.14 | Updated Date 09/17/2025 |
52 Weeks Range 3.76 - 29.14 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -47.45% | Operating Margin (TTM) -5.87% |
Management Effectiveness
Return on Assets (TTM) -5.44% | Return on Equity (TTM) -70.03% |
Valuation
Trailing PE - | Forward PE 53.48 | Enterprise Value 778034702 | Price to Sales(TTM) 0.84 |
Enterprise Value 778034702 | Price to Sales(TTM) 0.84 | ||
Enterprise Value to Revenue 0.93 | Enterprise Value to EBITDA -23.47 | Shares Outstanding 93044600 | Shares Floating 85677353 |
Shares Outstanding 93044600 | Shares Floating 85677353 | ||
Percent Insiders 2.9 | Percent Institutions 98.41 |
Upturn AI SWOT
Myriad Genetics Inc
Company Overview
History and Background
Myriad Genetics Inc. was founded in 1991. It initially focused on identifying genes related to common diseases. A significant milestone was the launch of its BRCA1 and BRCA2 gene testing for breast and ovarian cancer risk assessment. Over time, it has expanded its product portfolio to include other genetic tests for various diseases and conditions.
Core Business Areas
- Molecular Diagnostics: Offers a range of genetic tests to assess a person's risk of developing diseases or to guide treatment decisions. This segment includes testing for hereditary cancer, prenatal screening, and pharmacogenomics.
- Companion Diagnostics: Develops and markets companion diagnostic tests that help identify patients who are most likely to benefit from specific therapies. These tests are often developed in partnership with pharmaceutical companies.
Leadership and Structure
Paul J. Diaz is the President and CEO. The company has a board of directors and an executive leadership team overseeing various functions such as research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- BRACAnalysis CDx: A diagnostic test used to identify patients with advanced ovarian cancer who are eligible for treatment with PARP inhibitors. Market share is estimated to be around 50% in the US PARP inhibitor companion diagnostic market. Competitors include Foundation Medicine (FMI), Guardant Health (GH).
- Myriad Precise Oncology Solutions: Tests like Myriad Precise Tumor Sequencing (MPTS) and Myriad Precise Liquid. MPTS market share is lower since it's a newer offering. Competitors include Caris Life Sciences, Tempus.
- GeneSight: A pharmacogenomic test designed to help clinicians choose the right medication for patients with depression, anxiety, and other mental health conditions. While difficult to pinpoint exact market share due to the breadth of competitors and types of tests, it is considered a leader in the pharmacogenomics space for mental health. Competitors include Assurex Health (acquired by Myriad in 2016, divested in 2022).
Market Dynamics
Industry Overview
The molecular diagnostics industry is experiencing significant growth due to advancements in genomics, increasing awareness of personalized medicine, and the rising prevalence of genetic diseases. The industry is characterized by intense competition and rapid technological advancements.
Positioning
Myriad Genetics is positioned as a leader in genetic testing and personalized medicine. Its competitive advantages include a strong intellectual property portfolio, established brand recognition, and a comprehensive suite of genetic tests. However, pricing pressures and increasing competition pose challenges.
Total Addressable Market (TAM)
The TAM for molecular diagnostics is estimated to be tens of billions of dollars globally. Myriad is positioned to capture a portion of this market through its existing products and pipeline of new tests.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Extensive patent portfolio
- Established relationships with healthcare providers
- Comprehensive suite of genetic tests
Weaknesses
- Past pricing controversies
- Reliance on a few key products
- Competition from larger diagnostic companies
- Complex regulatory landscape
Opportunities
- Expanding into new geographic markets
- Developing new diagnostic tests for underserved diseases
- Partnering with pharmaceutical companies to develop companion diagnostics
- Leveraging data analytics to improve patient outcomes
Threats
- Increasing competition from other diagnostic companies
- Pricing pressures from payers and regulators
- Changes in reimbursement policies
- Patent challenges
Competitors and Market Share
Key Competitors
- FMI
- GH
- CSTL
- ILMN
Competitive Landscape
Myriad Genetics faces intense competition in the molecular diagnostics market. Its key competitive advantage lies in its established brand and comprehensive test portfolio. However, it faces challenges from larger companies with greater resources.
Major Acquisitions
Assurex Health
- Year: 2016
- Acquisition Price (USD millions): 385
- Strategic Rationale: Expanded Myriad's presence in pharmacogenomics and personalized medicine.
Crescendo Bioscience
- Year: 2014
- Acquisition Price (USD millions): 270
- Strategic Rationale: Expanded Myriadu2019s portfolio with a diagnostic test for rheumatoid arthritis.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by new product launches and expansion into new markets. However, competition and pricing pressures have impacted growth rates.
Future Projections: Analyst estimates vary depending on market conditions and product performance. Expect growth to be driven by personalized medicine and expansion into new therapeutic areas.
Recent Initiatives: Focus on precision oncology, expansion of companion diagnostics, and investment in data analytics capabilities.
Summary
Myriad Genetics is a key player in the genetic testing market with a strong brand and comprehensive test portfolio. It faces competitive pressures and past pricing controversies, but it has opportunities to expand into new markets and therapeutic areas. Focus on precision oncology and strategic partnerships could drive future growth. Careful attention to pricing strategies and competitive landscape are crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be exhaustive. Market share data is estimated and may vary. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Myriad Genetics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 1995-10-05 | President, CEO & Director Mr. Samraat S. Raha | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2700 | Website https://www.myriad.com |
Full time employees 2700 | Website https://www.myriad.com | ||
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.